Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 19:14:17588359221134065.
doi: 10.1177/17588359221134065. eCollection 2022.

Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up

Affiliations

Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up

Hannah Fluhrer et al. Ther Adv Med Oncol. .

Abstract

Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has substantially advanced over the last three decades, whereby data from controlled clinical trials indicate significant improvements regarding patients' overall survival (OS) in highly selected patient cohorts. The aim of this study is to evaluate the impact of potentially game changing drugs on patients' outcomes by comparing three different historical mRCC treatment eras.

Methods: In all, 914 mRCC patients who were diagnosed between July 1985 and September 2020 were included into this observational study and assigned to three different treatment eras ['cytokine', 'first-generation tyrosine kinase inhibitors (TKIs)', and 'modern TKIs/immunotherapy'] based on the EMA approval dates of sunitinib (July 2006) and nivolumab (June 2015) in mRCC treatment. OS was considered the primary study endpoint. Kaplan-Meier analyses, log-rank tests, and uni- and multivariable Cox regression models were performed.

Results: OS was significantly longer in patients of the modern TKIs/immunotherapy era (median OS not reached) as compared to the cytokine (2.4 years) and first-generation TKIs era (1.7 years, all p < 0.001). Moreover, patients of the modern TKIs/immunotherapy era demonstrated a significantly better prognosis [hazard ratio (HR): 0.41, 95% confidence interval (CI): 0.32-0.55, p < 0.001] compared to those of the cytokine era, while no statistically significant difference was observed between the cytokine and the first-generation TKIs era cohort (HR: 1.12, 95% CI: 0.89-1.41, p = 0.341). Subgroup analyses stratified by the International Metastatic RCC Database Consortium (IMDC) risk groups showed a significantly longer OS in the modern TKIs/immunotherapy era as compared to first-generation TKIs and cytokines across all IMDC risk groups.

Conclusion: Significant advances in the systemic medical treatment of mRCC during the recent decade and the introduction of immunotherapy exerted a major impact on patient outcomes in terms of OS in a real-life population.

Keywords: immunotherapy; interferon; outcomes; renal cell carcinoma; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
The Kaplan–Meier curves showing OS for cytokine, first-generation TKIs, and modern TKIs/immunotherapy era in the overall patient cohort (cytokine versus first-generation TKIs p = 0.118; cytokine versus modern TKIs/immunotherapy p < 0.001; first-generation TKIs versus modern TKIs/immunotherapy p < 0.001). OS, overall survival; TKIs, tyrosine kinase inhibitors.
Figure 2.
Figure 2.
The Kaplan–Meier curves showing OS for cytokine, first-generation TKIs, and modern TKIs/immunotherapy era in IMDC good risk group patients (cytokine versus first-generation TKIs p = 0.016; cytokine versus modern TKIs/immunotherapy p < 0.001; first-generation TKIs versus modern TKIs/immunotherapy p < 0.001). IMDC, international metastatic RCC database consortium; OS, overall survival; TKIs, tyrosine kinase inhibitors.
Figure 3.
Figure 3.
The Kaplan–Meier curves showing OS for cytokine, first-generation TKIs, and modern TKIs/immunotherapy era in IMDC intermediate risk group patients (cytokine versus first-generation TKIs p = 0.473; cytokine versus modern TKIs/immunotherapy p < 0.001; first-generation TKIs versus modern TKIs/immunotherapy p < 0.001). IMDC, international metastatic RCC database consortium; OS, overall survival; TKIs, tyrosine kinase inhibitors.
Figure 4.
Figure 4.
The Kaplan–Meier curves showing OS for cytokine, first-generation TKIs, and modern TKIs/immunotherapy era in IMDC poor risk group patients (cytokine versus first-generation TKIs p = 0.59; cytokine versus modern TKIs/immunotherapy p < 0.001; first-generation TKIs versus modern TKIs/immunotherapy p < 0.001). IMDC, international metastatic RCC database consortium; OS, overall survival; TKIs, tyrosine kinase inhibitors.

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, et al.. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7–33. - PubMed
    1. Ljungberg B, Albiges L, Abu-Ghanem Y, et al.. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019; 75: 799–810. - PubMed
    1. Inamura K. Renal cell tumors: understanding their molecular pathological epidemiology and the 2016 WHO classification. Int J Mol Sci 2017; 18: 2195. - PMC - PubMed
    1. Deleuze A, Saout J, Dugay F, et al.. Immunotherapy in renal cell carcinoma: the future is now. Int J Mol Sci 2020; 21: 2532. - PMC - PubMed
    1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477–2490. - PubMed